Hybrid coronary revascularization (HCR) versus coronary artery bypass grafting (CABG) in multivessel coronary artery disease (MVCAD): A meta-analysis of 14 studies comprising 4226 patients.
Sanjana NagrajAndreas TzoumasFotis KakargiasStefanos GiannopoulosAthina NtoumaziouDamianos G KokkinidisMiguel Alvarez VillelaAzeem LatibPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2022)
This meta-analysis suggests that HCR is feasible and safe for the treatment of MVCAD. However, benefits of HCR should be carefully weighed against the increased long-term risk of repeat-revascularization when selecting patients, and further studies evaluating differences in long-term mortality between HCR and CABG are required.
Keyphrases
- coronary artery bypass grafting
- coronary artery disease
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- systematic review
- newly diagnosed
- chronic kidney disease
- cardiovascular events
- prognostic factors
- st segment elevation myocardial infarction
- randomized controlled trial
- coronary artery
- st elevation myocardial infarction
- heart failure
- peritoneal dialysis
- cardiovascular disease
- meta analyses
- combination therapy